Pharmaceutical general manager Martin Shkreli, who is currently serving a prison sentence, filed a lawsuit Friday against three executives at his former pharmaceutical company Retrophin.
The so-called "pharmaceutical verve" said Retrophin's chairman, CEO and general counsel illegally expelled him from the company and stole $ 30 million. He affirms that these people benefited from his expulsion and were driven by "egos, jealousy and greed".
The lawsuit was filed in a federal court in Manhattan.
Shkreli was sentenced to seven years in prison after being convicted of securities fraud for allegedly running his business as a Ponzi scheme. While he lost millions of dollars from investors in bad operations, he is said to have paid for them with the profits he earned from his pharmaceutical company Retrophin.
Shkreli is also known for price speculation. In 2015, the infamous increase in the price of his anti-HIV drug, Daraprim, by 5,000 percent, to $ 750 per pill of $ 13.50, a decision he defended at that time.
CLICK HERE TO OBTAIN THE FOX BUSINESS APP
A judge determined that Shkreli was responsible for the $ 6.4 million that investors placed in their funds as a result of the fraud and $ 4 million for trying to inflate the price of Retrophin's stock while trying to prevent investors from selling their shares.
The Wall Street Journal reported that, while behind bars, Shkreli ran pharmaceutical company Phoenixus AG using a contraband cell phone. Since then he has been in solitary confinement.